Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 6Small Cell Lung Carcinoma 2Triple Negative Breast Neoplasms 1Intracranial Germ Cell CNS Tumor, Childhood 1Carcinoma, Neuroendocrine 1

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 29Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Gemcitabine 13apatinib 12Paclitaxel 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 8pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × EC regimen × Clear all
NCT06698965 2024-11-21

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

Shanghai Chest Hospital

Phase 2 Recruiting
52 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00812266 2016-01-26

Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

Danish Oncological Lung Cancer Group

Phase 3 Terminated
281 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡